143 related articles for article (PubMed ID: 38541851)
1. Texture Features of
Norikane T; Ishimura M; Mitamura K; Yamamoto Y; Arai-Okuda H; Manabe Y; Murao M; Morita R; Obata T; Tanaka K; Murota M; Kanaji N; Nishiyama Y
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38541851
[No Abstract] [Full Text] [Related]
2. Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
Hughes DJ; Josephides E; O'Shea R; Manickavasagar T; Horst C; Hunter S; Tanière P; Nonaka D; Van Hemelrijck M; Spicer J; Goh V; Bille A; Karapanagiotou E; Cook GJR
Eur Radiol; 2024 Feb; ():. PubMed ID: 38388716
[TBL] [Abstract][Full Text] [Related]
3. Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET.
Kim BS; Kang J; Jun S; Kim H; Pak K; Kim GH; Heo HJ; Kim YH
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8288-8295. PubMed ID: 32894535
[TBL] [Abstract][Full Text] [Related]
4. Predictive value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography for PD-L1 expression in non-small cell lung cancer: A systematic review and meta-analysis.
Seol HY; Kim YS; Kim SJ
Thorac Cancer; 2020 Nov; 11(11):3260-3268. PubMed ID: 32951338
[TBL] [Abstract][Full Text] [Related]
5. The Value of
Vekens K; Everaert H; Neyns B; Ilsen B; Decoster L
Clin Lung Cancer; 2021 Sep; 22(5):432-440. PubMed ID: 33879398
[TBL] [Abstract][Full Text] [Related]
6. [Construction of A Nomogram Prediction Model for PD-L1 Expression
in Non-small Cell Lung Cancer Based on 18F-FDG PET/CT Metabolic Parameters].
Hao L; Wang L; Zhang M; Yan J; Zhang F
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):833-842. PubMed ID: 38061885
[TBL] [Abstract][Full Text] [Related]
7. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on
Takada K; Toyokawa G; Okamoto T; Baba S; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Honda H; Oda Y; Maehara Y
Cancer Med; 2017 Nov; 6(11):2552-2561. PubMed ID: 28980429
[TBL] [Abstract][Full Text] [Related]
8. The correlation between PD-L1 expression and metabolic parameters of
Xu X; Li J; Yang Y; Sang S; Deng S
Clin Imaging; 2022 Sep; 89():120-127. PubMed ID: 35797878
[TBL] [Abstract][Full Text] [Related]
9. Predicting PD-L1 expression status in patients with non-small cell lung cancer using [
Zhao X; Zhao Y; Zhang J; Zhang Z; Liu L; Zhao X
EJNMMI Res; 2023 Jan; 13(1):4. PubMed ID: 36682020
[TBL] [Abstract][Full Text] [Related]
10. A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer.
Lim CH; Koh YW; Hyun SH; Lee SJ
Anticancer Res; 2022 Dec; 42(12):5875-5884. PubMed ID: 36456151
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of volume-based 18F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma.
Wang D; Li Y; Chen X; Li P
Medicine (Baltimore); 2021 Sep; 100(35):e27100. PubMed ID: 34477147
[TBL] [Abstract][Full Text] [Related]
12. Standardized 18F-FDG PET/CT radiomic features provide information on PD-L1 expression status in treatment-naïve patients with non-small cell lung cancer.
Zhang R; Hohenforst-Schmidt W; Steppert C; Sziklavari Z; Schmidkonz C; Atzinger A; Kuwert T; Klink T; Sterlacci W; Hartmann A; Vieth M; Förster S
Nuklearmedizin; 2022 Oct; 61(5):385-393. PubMed ID: 35768005
[TBL] [Abstract][Full Text] [Related]
13. New insight on the correlation of metabolic status on
Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
[TBL] [Abstract][Full Text] [Related]
14. The "digital biopsy" in non-small cell lung cancer (NSCLC): a pilot study to predict the PD-L1 status from radiomics features of [18F]FDG PET/CT.
Monaco L; De Bernardi E; Bono F; Cortinovis D; Crivellaro C; Elisei F; L'Imperio V; Landoni C; Mathoux G; Musarra M; Pagni F; Turolla EA; Messa C; Guerra L
Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3401-3411. PubMed ID: 35403860
[TBL] [Abstract][Full Text] [Related]
15. Association between
Zhao L; Liu J; Wang H; Shi J
Br J Radiol; 2021 Mar; 94(1119):20200397. PubMed ID: 33492995
[TBL] [Abstract][Full Text] [Related]
16. Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[
Wu C; Cui Y; Liu J; Ma L; Xiong Y; Gong Y; Zhao Y; Zhang X; Chen S; He Q; Zhang J; Liu M; Fan Y
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4054-4066. PubMed ID: 33978830
[TBL] [Abstract][Full Text] [Related]
17.
Hu B; Chen W; Zhang Y; Shi H; Cheng D; Xiu Y
Ann Nucl Med; 2020 May; 34(5):322-328. PubMed ID: 32130663
[TBL] [Abstract][Full Text] [Related]
18. Beads phantom for evaluating heterogeneity of SUV on
Okuda K; Saito H; Yamashita S; Yamamoto H; Ichikawa H; Kato T; Yokoyama K; Doai M; Hashimoto M; Matoba M
Ann Nucl Med; 2022 May; 36(5):495-503. PubMed ID: 35377093
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and specificity of amide proton transfer-weighted imaging for assessing programmed death-ligand 1 status in non-small cell lung cancer: a comparative study with intravoxel incoherent motion and
Meng N; Fu F; Sun J; Feng P; Luo Y; Wu Y; Li X; Yuan J; Yang Y; Liu H; Wang Z; Wang M
Quant Imaging Med Surg; 2022 Sep; 12(9):4474-4487. PubMed ID: 36060584
[TBL] [Abstract][Full Text] [Related]
20. Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study.
Takada K; Toyokawa G; Azuma K; Takamori S; Jogo T; Hirai F; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
In Vivo; 2018; 32(6):1541-1550. PubMed ID: 30348714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
